Chronos Archive seal
The Human Record

Ada Lovelace

Case HR-NI031 · Modern EHR teaching episode · Draft for review

Review summary

Historical dates
December 10, 1815 – November 27, 1852
Synthetic DOB
1990-12-10
Index visit
2026-06-02 at age 35
Synthetic MRN
HR-NI031-SYN

Teaching objective: Primary care, gynecologic oncology and early palliative care for a 35-year-old mathematician with five months of abnormal bleeding and pelvic pain who has taken prescribed opium tincture for years: speculum examination and biopsy of a visible cervical tumor at the first visit, with tumor HPV typing; intravenous iron for iron deficiency anemia from blood loss; conversion of an unmeasured opium tincture to measured oral morphine, then long-acting morphine, with naloxone, a bowel regimen, safe storage and a prescription monitoring check, applying the ASCO 2023 guideline on opioids for cancer pain and noting that the CDC 2022 opioid guideline does not cover cancer pain; FIGO 2018 staging with MRI and PET-CT and biopsy of a lung metastasis (stage IVB); tumor biomarkers (PD-L1, mismatch repair, HER2) and why germline testing is not indicated; palliative pelvic radiation for bleeding; first-line carboplatin, paclitaxel and pembrolizumab under the NCCN cervical cancer guideline and KEYNOTE-826, without bevacizumab while she was bleeding after pelvic radiation; specialist palliative care from diagnosis (ASCO 2024); immune-related thyroid monitoring; opioid-induced constipation; goals-of-care conversations and advance care planning; vaccination of an adult on chemotherapy; and protecting clear-headed hours for her mathematical work.

Historical timeline

DateEventClaims
December 10, 1815Born in Piccadilly, London.CLM-0001
1829Measles, with a long recovery and a year in bed.CLM-0002
July 8, 1835Married; Countess of Lovelace from 1838.CLM-0003
1837Cholera, with lingering asthma and digestive problems.CLM-0004
1842 to 1843Translation of Menabrea's article on the Analytical Engine, with her Notes.CLM-0006
1843 to 1844 and laterDeclining health; several medicines; laudanum and opium.CLM-0005, CLM-0007
about 1850 to 1852Gambling on horses and pawned jewels.CLM-0008
1851Gravely ill with uterine cancer.CLM-0010
January 1852Wracked with pain as the cancer advanced.CLM-0011
November 27, 1852Died in Marylebone, London; owed about 2,000 pounds in gambling debts.CLM-0009, CLM-0012

Evidence claims

D = documented, R = retrospective, S = synthetic.

GradeClaimCertaintySources
D Augusta Ada Byron was born on December 10, 1815, in Piccadilly, London, the daughter of the poet Lord Byron and Anne Isabella Byron. confirmed McCarthy L. About Ada Lovelace (Ada Lovelace blog) supports
O'Connor JJ, Robertson EF. Augusta Ada King, Countess of Lovelace (MacTutor History of Mathematics) supports
D She was often ill as a child. In 1829, at 13, she caught measles, from which she took a long while to recover; she was bedridden for a whole year.
Documented childhood illness. The brief's 'unable to walk' and later crutches were not found in a fetched source and are not recorded.
confirmed O'Connor JJ, Robertson EF. Augusta Ada King, Countess of Lovelace (MacTutor History of Mathematics) supports
Zielinski S. Who Was Ada Lovelace? Smithsonian Magazine, March 24, 2010 supports
D On July 8, 1835, she married William King, who was created an earl in 1838, making her Countess of Lovelace. confirmed McCarthy L. About Ada Lovelace (Ada Lovelace blog) supports
O'Connor JJ, Robertson EF. Augusta Ada King, Countess of Lovelace (MacTutor History of Mathematics) supports
D Her health suffered after a bout of cholera in 1837, and she had lingering problems with asthma and her digestive system.
Documented in a general biography only.
probable Biography.com Editors. Ada Lovelace Biography (last updated May 6, 2021) supports
D Her doctors gave her painkillers such as laudanum and opium; she reportedly had mood swings and hallucinations.
Documented in a general biography only; no doses or dates are given. Anchors the modern history of long-term prescribed opium tincture; no substance use disorder is inferred.
probable Biography.com Editors. Ada Lovelace Biography (last updated May 6, 2021) supports
D Between 1842 and 1843 she translated L. F. Menabrea's article on Charles Babbage's Analytical Engine and added her own extensive Notes, published in 1843 under the initials A.A.L. The Notes, which include a method for computing Bernoulli numbers on the engine, are often described as the first published computer program.
Her mathematical work; anchors the modern goal of clear-headed working hours.
confirmed McCarthy L. About Ada Lovelace (Ada Lovelace blog) supports
O'Connor JJ, Robertson EF. Augusta Ada King, Countess of Lovelace (MacTutor History of Mathematics) supports
Exploding the myths of Ada Lovelace's mathematics supports
D Her health, always fragile, declined sharply after 1843. By the end of that year she was taking several medicines for different health problems; in 1844 she wrote that a recent illness had left her 'utterly unable to think even of my studies', and she thought of writing a scientific study of the effects of opium and wine based on her own experience. In the 1840s she had what she called heart or rheumatic attacks.
Documented chronic ill health and her own use of opium; no diagnosis is inferred.
confirmed McCarthy L. About Ada Lovelace (Ada Lovelace blog) supports
O'Connor JJ, Robertson EF. Augusta Ada King, Countess of Lovelace (MacTutor History of Mathematics) supports
Zielinski S. Who Was Ada Lovelace? Smithsonian Magazine, March 24, 2010 supports
D Gambling on horses was a passion of her later years, and she pawned some of her jewels to finance it.
Documented gambling; the years are not given exactly. No gambling disorder is inferred.
probable O'Connor JJ, Robertson EF. Augusta Ada King, Countess of Lovelace (MacTutor History of Mathematics) supports
D As she lay dying it came out that she had led a ruinous horse-betting ring, borrowed money from shady people, and pawned her diamonds twice; she owed about 2,000 pounds in gambling debts when she died.
After the episode.
probable Warr T. Review of Miranda Seymour, In Byron's Wake. Historical Novels Review 85 (August 2018) supports
O'Connor JJ, Robertson EF. Augusta Ada King, Countess of Lovelace (MacTutor History of Mathematics) supports
D By 1851 she was extremely sick with uterine cancer.
Documented; the site is given as the uterus, and the modern episode's cervical primary is a synthetic choice.
confirmed Zielinski S. Who Was Ada Lovelace? Smithsonian Magazine, March 24, 2010 supports
Warr T. Review of Miranda Seymour, In Byron's Wake. Historical Novels Review 85 (August 2018) supports
D By January 1852 she was wracked with pain as the cancer became more acute.
After the episode.
confirmed O'Connor JJ, Robertson EF. Augusta Ada King, Countess of Lovelace (MacTutor History of Mathematics) supports
D She died on November 27, 1852, in Marylebone, London, at 36, the age at which her father had died, and was buried at her request next to her father at the Church of St. Mary Magdalene in Hucknall, Nottinghamshire.
After the episode.
confirmed McCarthy L. About Ada Lovelace (Ada Lovelace blog) supports
O'Connor JJ, Robertson EF. Augusta Ada King, Countess of Lovelace (MacTutor History of Mathematics) supports
Biography.com Editors. Ada Lovelace Biography (last updated May 6, 2021) supports
Augusta Ada King (nee Byron), Countess of Lovelace (Revolution exhibit) supports

Modern synthetic problem list

GradeProblemClinical statusVerificationPlacementHistorical claims
S Bleeding between periods and after intercourse, with heavier periods, a watery blood-stained discharge and a constant pelvic ache, for about five months; average pain 7 of 10 despite her opium tincture; a friable cervical mass found on examination and biopsied; cause not yet established at intake resolved confirmed active CLM-0010
S Iron deficiency anemia from chronic blood loss: hemoglobin 8.4 g/dL, mean cell volume 74 fL, ferritin 5 ng/mL, with tiredness and breathlessness on stairs active confirmed active CLM-0010
S Adenocarcinoma of the endocervix, usual (HPV-associated) type, HPV 18 positive, FIGO 2018 stage IVB: a 5.2 cm tumor with left parametrial invasion, metastases to left pelvic and para-aortic lymph nodes, and bilateral lung metastases on MRI and PET-CT; PD-L1 combined positive score 5, mismatch repair proficient, HER2 1+; treated with palliative pelvic radiation for bleeding and carboplatin, paclitaxel and pembrolizumab, with specialist palliative care from diagnosis active confirmed active CLM-0010
S Cancer-related pelvic pain, nociceptive and visceral, from the cervical tumor and its left parametrial extension active confirmed active CLM-0010
S Long-term prescribed opioid therapy: opium tincture for recurrent pelvic and abdominal pain for about two years, measured at times with a household spoon, converted at intake to measured oral morphine; no opioid use disorder on a DSM-5 assessment; naloxone supplied active confirmed active CLM-0005, CLM-0007
S Drug-induced constipation from long-acting morphine and ondansetron, a week after the first chemotherapy cycle: no bowel movement for five days, with bloating and cramping but passing wind, without vomiting; no bowel obstruction on examination; potassium and calcium normal; resolved with laxatives resolved confirmed active

Synthetic outcome measures

GradeDateMeasureResultCoding
S 2026-06-02 Hemoglobin [Mass/volume] in Blood 8.4 g/dL (low)
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-06-02 MCV [Entitic mean volume] in Red Blood Cells by Automated count 74 fL (low)
Reference 80-100 fL
http://loinc.org · 787-2
S 2026-06-02 Leukocytes [#/volume] in Blood by Automated count 7.8 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-06-02 Platelets [#/volume] in Blood by Automated count 412 10*3/uL (high)
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-06-02 Ferritin [Mass/volume] in Serum or Plasma 5 ng/mL (low)
Reference 15-150 ng/mL
http://loinc.org · 2276-4
S 2026-06-02 Creatinine [Mass/volume] in Serum or Plasma 0.68 mg/dL
Reference 0.57-1 mg/dL
http://loinc.org · 2160-0
S 2026-06-02 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 18 U/L
Reference 7-35 U/L
http://loinc.org · 1742-6
S 2026-06-02 Albumin [Mass/volume] in Serum or Plasma 3.6 g/dL
Reference 3.5-5 g/dL
http://loinc.org · 1751-7
S 2026-06-02 Choriogonadotropin.beta subunit [Units/volume] in Serum or Plasma 1 m[IU]/mL
Reference Below 5 is negative
http://loinc.org · 21198-7
S 2026-06-02 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 116 mL/min/1.73 m²
Reference 60 or more
http://loinc.org · 98979-8
S 2026-06-02 Pain severity - 0-10 verbal numeric rating [Score] - Reported 7 http://loinc.org · 72514-3
S 2026-06-02 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 8 http://loinc.org · 44261-6
S 2026-06-16 Hemoglobin [Mass/volume] in Blood 9 g/dL (low)
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-06-16 Creatinine [Mass/volume] in Serum or Plasma 0.66 mg/dL
Reference 0.57-1 mg/dL
http://loinc.org · 2160-0
S 2026-06-16 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 17 U/L
Reference 7-35 U/L
http://loinc.org · 1742-6
S 2026-06-16 Thyrotropin [Units/volume] in Serum or Plasma 1.9 mIU/L
Reference 0.45-4.5 mIU/L
http://loinc.org · 3016-3
S 2026-06-16 Thyroxine (T4) free [Mass/volume] in Serum or Plasma 1.2 ng/dL
Reference 0.8-1.8 ng/dL
http://loinc.org · 3024-7
S 2026-06-16 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 117 mL/min/1.73 m²
Reference 60 or more
http://loinc.org · 98979-8
S 2026-06-16 Pain severity - 0-10 verbal numeric rating [Score] - Reported 6 http://loinc.org · 72514-3
S 2026-07-07 Potassium [Moles/volume] in Serum or Plasma 3.8 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-07-07 Calcium [Mass/volume] in Serum or Plasma 9.3 mg/dL
Reference 8.6-10.3 mg/dL
http://loinc.org · 17861-6
S 2026-07-14 Hemoglobin [Mass/volume] in Blood 9.8 g/dL (low)
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-07-14 Leukocytes [#/volume] in Blood by Automated count 4.1 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-07-14 Neutrophils [#/volume] in Blood by Automated count 2.2 10*3/uL
Reference 1.8-7.7 10*3/uL
http://loinc.org · 751-8
S 2026-07-14 Platelets [#/volume] in Blood by Automated count 236 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-07-14 Creatinine [Mass/volume] in Serum or Plasma 0.7 mg/dL
Reference 0.57-1 mg/dL
http://loinc.org · 2160-0
S 2026-07-14 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 22 U/L
Reference 7-35 U/L
http://loinc.org · 1742-6
S 2026-07-14 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 116 mL/min/1.73 m²
Reference 60 or more
http://loinc.org · 98979-8
S 2026-07-14 Pain severity - 0-10 verbal numeric rating [Score] - Reported 3 http://loinc.org · 72514-3
S 2026-07-14 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 9 http://loinc.org · 44261-6
S 2026-09-08 Hemoglobin [Mass/volume] in Blood 10.6 g/dL (low)
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-09-08 Leukocytes [#/volume] in Blood by Automated count 3.8 10*3/uL (low)
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-09-08 Neutrophils [#/volume] in Blood by Automated count 1.9 10*3/uL
Reference 1.8-7.7 10*3/uL
http://loinc.org · 751-8
S 2026-09-08 Platelets [#/volume] in Blood by Automated count 172 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-09-08 Creatinine [Mass/volume] in Serum or Plasma 0.72 mg/dL
Reference 0.57-1 mg/dL
http://loinc.org · 2160-0
S 2026-09-08 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 26 U/L
Reference 7-35 U/L
http://loinc.org · 1742-6
S 2026-09-08 Thyrotropin [Units/volume] in Serum or Plasma 3.4 mIU/L
Reference 0.45-4.5 mIU/L
http://loinc.org · 3016-3
S 2026-09-08 Ferritin [Mass/volume] in Serum or Plasma 210 ng/mL (high)
Reference 15-150 ng/mL
http://loinc.org · 2276-4
S 2026-09-08 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 112 mL/min/1.73 m²
Reference 60 or more
http://loinc.org · 98979-8
S 2026-09-08 Pain severity - 0-10 verbal numeric rating [Score] - Reported 3 http://loinc.org · 72514-3
S 2026-09-08 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 7 http://loinc.org · 44261-6
S 2026-10-20 Hemoglobin [Mass/volume] in Blood 10.9 g/dL (low)
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-10-20 Leukocytes [#/volume] in Blood by Automated count 4.2 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-10-20 Neutrophils [#/volume] in Blood by Automated count 2.4 10*3/uL
Reference 1.8-7.7 10*3/uL
http://loinc.org · 751-8
S 2026-10-20 Platelets [#/volume] in Blood by Automated count 188 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-10-20 Creatinine [Mass/volume] in Serum or Plasma 0.71 mg/dL
Reference 0.57-1 mg/dL
http://loinc.org · 2160-0
S 2026-10-20 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 U/L
Reference 7-35 U/L
http://loinc.org · 1742-6
S 2026-10-20 Thyrotropin [Units/volume] in Serum or Plasma 7.8 mIU/L (high)
Reference 0.45-4.5 mIU/L
http://loinc.org · 3016-3
S 2026-10-20 Thyroxine (T4) free [Mass/volume] in Serum or Plasma 1 ng/dL
Reference 0.8-1.8 ng/dL
http://loinc.org · 3024-7
S 2026-10-20 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 114 mL/min/1.73 m²
Reference 60 or more
http://loinc.org · 98979-8
S 2026-10-20 Pain severity - 0-10 verbal numeric rating [Score] - Reported 2 http://loinc.org · 72514-3
S 2026-10-20 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 5 http://loinc.org · 44261-6
S 2026-08-18 Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 2 http://loinc.org · 55758-7

Synthetic vital signs

DateMeasureResultLOINCGrade
2026-06-02Body height165 cm8302-2S
2026-06-02Body weight54 kg29463-7S
2026-06-02Body mass index (BMI) [Ratio]19.8 kg/m239156-5S
2026-06-02Systolic blood pressure108 mm[Hg]8480-6S
2026-06-02Diastolic blood pressure68 mm[Hg]8462-4S
2026-06-02Heart rate96 /min8867-4S
2026-06-02Respiratory rate16 /min9279-1S
2026-06-02Body temperature36.8 Cel8310-5S
2026-06-02Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2026-06-16Body height165 cm8302-2S
2026-06-16Body weight54.2 kg29463-7S
2026-06-16Body mass index (BMI) [Ratio]19.9 kg/m239156-5S
2026-06-16Systolic blood pressure106 mm[Hg]8480-6S
2026-06-16Diastolic blood pressure66 mm[Hg]8462-4S
2026-06-16Heart rate92 /min8867-4S
2026-06-16Respiratory rate16 /min9279-1S
2026-06-16Body temperature36.7 Cel8310-5S
2026-06-16Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2026-07-14Body height165 cm8302-2S
2026-07-14Body weight53.4 kg29463-7S
2026-07-14Body mass index (BMI) [Ratio]19.6 kg/m239156-5S
2026-07-14Systolic blood pressure110 mm[Hg]8480-6S
2026-07-14Diastolic blood pressure70 mm[Hg]8462-4S
2026-07-14Heart rate84 /min8867-4S
2026-07-14Respiratory rate16 /min9279-1S
2026-07-14Body temperature36.6 Cel8310-5S
2026-07-14Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2026-09-08Body height165 cm8302-2S
2026-09-08Body weight54 kg29463-7S
2026-09-08Body mass index (BMI) [Ratio]19.8 kg/m239156-5S
2026-09-08Systolic blood pressure112 mm[Hg]8480-6S
2026-09-08Diastolic blood pressure70 mm[Hg]8462-4S
2026-09-08Heart rate80 /min8867-4S
2026-09-08Respiratory rate16 /min9279-1S
2026-09-08Body temperature36.7 Cel8310-5S
2026-09-08Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2026-10-20Body height165 cm8302-2S
2026-10-20Body weight54.4 kg29463-7S
2026-10-20Body mass index (BMI) [Ratio]20 kg/m239156-5S
2026-10-20Systolic blood pressure114 mm[Hg]8480-6S
2026-10-20Diastolic blood pressure72 mm[Hg]8462-4S
2026-10-20Heart rate78 /min8867-4S
2026-10-20Respiratory rate16 /min9279-1S
2026-10-20Body temperature36.6 Cel8310-5S
2026-10-20Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2026-08-18Body height165 cm8302-2S
2026-08-18Body weight53.6 kg29463-7S
2026-08-18Body mass index (BMI) [Ratio]19.7 kg/m239156-5S
2026-08-18Systolic blood pressure110 mm[Hg]8480-6S
2026-08-18Diastolic blood pressure70 mm[Hg]8462-4S
2026-08-18Heart rate80 /min8867-4S
2026-08-18Respiratory rate16 /min9279-1S
2026-08-18Body temperature36.6 Cel8310-5S
2026-08-18Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2026-07-07Body height165 cm8302-2S
2026-07-07Body weight53.8 kg29463-7S
2026-07-07Body mass index (BMI) [Ratio]19.8 kg/m239156-5S
2026-07-07Systolic blood pressure110 mm[Hg]8480-6S
2026-07-07Diastolic blood pressure70 mm[Hg]8462-4S
2026-07-07Heart rate88 /min8867-4S
2026-07-07Respiratory rate16 /min9279-1S
2026-07-07Body temperature36.7 Cel8310-5S
2026-07-07Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S

Social, functional, and mental status

Social history

Functional status

Mental status

Allergies and medications

Allergies

Medications

Procedures and immunizations

Procedures

Immunizations

Past medical history

True biography with historical dates; not part of the synthetic care timeline.

Family history

Care-plan goals

GoalTarget dateStatusOutcome
Average pelvic pain at or below 3 of 10 without daytime sedation2026-07-14completedAverage pain 3 of 10 after radiation, on long-acting morphine, without daytime sleepiness
Bleeding controlled and hemoglobin above 10 g/dL without transfusion2026-09-08completedNo bleeding since radiation; hemoglobin 10.6 g/dL
A documented goals-of-care conversation and a named health care agent2026-09-08completedAdvance care plan and goals-of-care conversation recorded
Able to work on her mathematics for at least two hours most mornings2026-10-20completedWorking most mornings

Interventions

InterventionStatusGuideline
Gynecologic oncology consultation in two weeks for a friable cervical mass with bleeding and pain, biopsied today: diagnosis, staging, treatment intent, bleeding control, and paincompletedGL-NCCN-CERV-2026, GL-FIGO-2018
Stop opium tincture and change to measured oral morphine solution 5 mg every 4 hours as needed with an oral syringe, with acetaminophen, senna and polyethylene glycol, a naloxone nasal spray, a prescription monitoring check, locked storage, one prescriber, and review in two weekscompletedGL-ASCO-OPIOID-2023, GL-CDC-OPIOID-2022
Iron deficiency anemia: ferric carboxymaltose 750 mg intravenously today and in two weeks, with a blood count at each visit and ferritin 6 to 8 weeks after the infusionscompletedGL-CMID-2026
Blood tests: blood count, ferritin, creatinine, ALT, albumin and a pregnancy test; HIV, hepatitis B and hepatitis C tests before any cancer treatment; PHQ-9completedGL-ASCO-HBV-2020, GL-USPSTF-DEP-2023
Staging by FIGO 2018 with pelvic MRI and PET-CT, and a CT-guided biopsy of a lung nodule; tumor PD-L1, mismatch repair and HER2 testing; no germline testing, because cervical cancer is not a hereditary cancer syndromecompletedGL-NCCN-CERV-2026, GL-FIGO-2018
Palliative pelvic radiation, 20 Gy in 5 fractions, for bleeding and pain, then carboplatin, paclitaxel and pembrolizumab every 3 weeks for six cycles with pembrolizumab continuing, without bevacizumab while bleeding and after pelvic radiation; blood counts before each cycle and thyroid tests every six weekscompletedGL-NCCN-CERV-2026, GL-KN826-2021
Specialist palliative care alongside cancer treatment from diagnosis, for pain, symptoms, mood, and goals-of-care conversations, with long-acting morphine 15 mg every 12 hours and oral morphine 5 mg as needed for breakthrough paincompletedGL-ASCO-PALL-2024, GL-ASCO-OPIOID-2023, GL-ASCO-COMM-2026

Planned encounters

Supporting documents

C-CDA note documents

Each link opens a readable copy; the XML beside it is the exchange file.

Sources

IDSourcePublisherType
SRC-0001 McCarthy L. About Ada Lovelace (Ada Lovelace blog) Bodleian Libraries, University of Oxford other
SRC-0002 O'Connor JJ, Robertson EF. Augusta Ada King, Countess of Lovelace (MacTutor History of Mathematics) University of St Andrews scholarly
SRC-0003 Zielinski S. Who Was Ada Lovelace? Smithsonian Magazine, March 24, 2010 Smithsonian Magazine other
SRC-0004 Biography.com Editors. Ada Lovelace Biography (last updated May 6, 2021) A&E Television Networks (Biography.com) other
SRC-0005 Warr T. Review of Miranda Seymour, In Byron's Wake. Historical Novels Review 85 (August 2018) Historical Novel Society other
SRC-0006 Augusta Ada King (nee Byron), Countess of Lovelace (Revolution exhibit) Computer History Museum other
SRC-0007 Exploding the myths of Ada Lovelace's mathematics Mathematical Institute, University of Oxford scholarly
SRC-0008 HISTMED Master Roster v3 The Human Record project other

Review status

ReviewStatusNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check the opium tincture to morphine conversion and titration, the stage IVB staging and lung biopsy, palliative radiation before systemic therapy, the omission of bevacizumab, the immune-related thyroid monitoring, the opioid taper, and the early palliative care.
provenance reviewnot_startedThe Bodleian Libraries, the MacTutor archive (University of St Andrews), Smithsonian Magazine, Biography.com, a Historical Novels Review summary of Miranda Seymour's biography, the Computer History Museum and the Oxford Mathematical Institute logged. The laudanum and opium claim rests on a general biography and on her own words about opium and is graded probable. Bloodletting, cannabis and the details of the final illness were not verified and are left out.
safe messaging reviewnot_startedClaims about opium, laudanum, gambling and debts are marked sensitive. The modern PHQ-9 scores (8, 9, 7, 5) are synthetic and below 10; no behavioral-health or substance use diagnosis is made, and no safety assessment is required. The modern episode makes no prediction about her death.

Comments and corrections

Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.

Comments appear on the online version of this page.